News | January 26, 2022
Torrent Pharmaceuticals consolidated PAT at Rs 249 cr
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Go-ahead for pivotal clinical trial which is expected to commence by March
Biocon has reported consolidated financial results for the period ended December 31, 2021
Narayanan to lead SeQuent through next phase of consolidation and growth
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
The transaction is expected to close in the first quarter of 2022
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Biogen paid Ionis a US $ 60 million one-time upfront payment
Subscribe To Our Newsletter & Stay Updated
